Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhou, X. J.
Right arrow Articles by Vaziri, N. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, X. J.
Right arrow Articles by Vaziri, N. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 992-997
© 2002 European Renal Association-European Dialysis and Transplant Association

Defective calcium signalling in uraemic platelets and its amelioration with long-term erythropoietin therapy

Xin J. Zhou1, and Nosratola D. Vaziri2

1 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas and 2 Division of Nephrology and Hypertension, University of California at Irvine, Irvine, California, USA

Background. Chronic renal failure (CRF) is associated with prolonged bleeding time and impaired platelet adhesion and aggregation. Erythropoietin (Epo) administration improves platelet adhesion/aggregation and ameliorates prolongation of bleeding time in CRF. However, the mechanisms of improved platelet function after Epo therapy have not been fully elucidated. The present study examined the hypothesis that the improved uraemic platelet function after Epo therapy is, in part, due to correction of the platelet calcium signalling.

Methods. Rats were randomized into four groups after 5/6 nephrectomies to produce CRF. The Epo-treated CRF group received Epo, 150 U/kg, twice weekly for 6 weeks to prevent anaemia; the felodipine and Epo-treated CRF group received Epo but was kept normotensive by felodipine treatment; the placebo-treated CRF group received placebo injections and became anaemic; and the iron-deficient CRF group received Epo but was kept anaemic by dietary iron-deficiency. A group of sham-operated rats was included as normal control. Basal and thrombin-stimulated platelet cytosolic calcium ([Ca2+]i) were determined using a Ca2+-sensitive dye (fura-2).

Results. Platelets from placebo-treated CRF group exhibited a profound attenuation of thrombin-stimulated surge in [Ca2+]i, which is the final pathway of platelet activation. Long-term Epo administration led to a normalization of the thrombin-induced rise in platelet [Ca2+]i in the CRF animals, independent of either haematocrit or blood pressure values. Further studies revealed that improved Ca2+ signalling with Epo is associated with increased Ca2+ uptake and expanded Ca2+ stores in the platelets.

Conclusions. The defective Ca2+ signalling in uraemic animals and its improvement with chronic Epo therapy provides the biochemical basis of the previously reported platelet dysfunction and prolonged bleeding time in uraemic patients and animals, and their amelioration with chronic Epo therapy.

Keywords: anaemia; bleeding time; cytosolic calcium; erythropoietin; hypertension; platelets; uraemia

Correspondence and offprint requests to: Xin J. Zhou, Division of Renal Pathology, Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard CS3.114, Dallas, TX 75390-9073, USA. Email: Joseph.zhou{at}UTsouthwestern.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
M. Trovati and F. Cavalot
Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
K. J Smith, A. J Bleyer, W. C Little, and D. C Sane
The cardiovascular effects of erythropoietin
Cardiovasc Res, September 1, 2003; 59(3): 538 - 548.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.